Clinical Trials Logo

Filter by:
NCT ID: NCT00642278 Completed - Clinical trials for Diabetes Mellitus, Type II

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Start date: April 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.

NCT ID: NCT00641745 Completed - Schizophrenia Clinical Trials

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Start date: March 2008
Phase: Phase 3
Study type: Interventional

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.

NCT ID: NCT00640991 Completed - Clinical trials for Cardiovascular Diseases

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)

RECREATE Pilot
Start date: April 2008
Phase: Phase 3
Study type: Interventional

Insulin will safely reduce glucose levels in patients with acute ST-elevation myocardial infarction and admission hyperglycemia.

NCT ID: NCT00639483 Completed - Schizophrenia Clinical Trials

Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

Start date: March 2003
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia

NCT ID: NCT00637377 Completed - Clinical trials for Macular Degeneration

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

VIEW 2
Start date: April 2008
Phase: Phase 3
Study type: Interventional

This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.

NCT ID: NCT00637169 Completed - Clinical trials for Respiratory Insufficiency of Prematurity

Canadian Oxygen Trial (COT)

COT
Start date: December 2006
Phase: Phase 3
Study type: Interventional

Study Question: In infants who are born at gestational ages of 23 0/7 to 27 6/7 weeks, does lowering the concentration of supplemental oxygen to target an arterial oxygen saturation by pulse oximetry (SpO2)of 85-89% compared with 91-95%, from the day of birth until the baby's first discharge home, increase the probability of survival without severe neurosensory disability to a corrected age of 18 months?

NCT ID: NCT00636636 Completed - Clinical trials for Neuralgia,Postherpetic

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

Start date: March 2008
Phase: Phase 3
Study type: Interventional

Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.

NCT ID: NCT00636064 Completed - Pain Clinical Trials

A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery

NCT ID: NCT00635427 Completed - Clinical trials for Gaucher Disease, Type 1

An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

Start date: March 13, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of every other week dosing of Gene-Activated® human glucocerebrosidase (GA-GCB, velaglucerase alfa) intravenously in patients with type 1 Gaucher disease.

NCT ID: NCT00634049 Completed - Aspergillosis Clinical Trials

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

VITAL
Start date: April 22, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.